拉莫三嗪对成年癫(痫)患者血清中瘦素、抵抗素和脂联素水平的影响

摘要

Objective To explore the levels of serum leptin, adiponectin and resistin in patients of epilepsy.Methods The serum adiponectin, resistin and leptin were detected in 60 women with epilepsy and 30 healthy women. The patients were divided randomly into lamotrigine treatment group and valproate treatment group. Results Bodymass index,levels of serum leptin, adiponectin and resistin levels had no differences between lamotrigine treatment group and control group. Bodymass index, leptin and adiponectin levels were significantly higher in the valproate treatment group than those in the control group. But Adi levels were significantly lower in the valproate treatment group than those in the control group. Conclusion Lamotrigine therapy can not lead to weight gain. The serum leptin,adiponectin and resistin take part in the development of obesity.%目的 探讨抗癫(痫)新药拉莫三嗪对成年癫(痫)患者血清瘦素、抵抗素、脂联素水平的影响.方法 对30名女性健康查体人员和60例首发癫(疒 间)全面性强直-阵挛发作女性患者随机分为拉莫三嗪组和丙戊酸钠组,在治疗前和治疗后分别进行血清瘦素、抵抗素和脂联素水平测定,并测量腰臀比(帆)、体重指数(BMI).结果 拉莫三嗪治疗后、对照组BMI、WHR及血清瘦素、抵抗素、脂联素水平间均无明显差异,而丙戊酸钠治疗后血清瘦素、抵抗素水平明显升高,脂联素水平明显降低(P<0.01).结论 拉莫三嗪治疗不引起癫(痫)患者体重增加,瘦素、脂联素、抵抗素水平可能是肥胖发生的预测指标.